Tuesday, December 13, 2022
Access Vascular, Inc. (AVI) today announced that Riverside Medical Center, located just outside the Chicago area, was the first in the nation to use its HydroPICC® Dual-Lumen catheter in a patient. Made from a proprietary hydrophilic biomaterial featuring MIMIX™ technology, the device was inserted by Dr. Howard Roth at the level-two trauma Magnet® hospital in a patient experiencing complications with their existing polyurethane catheter.
Approximately 85% of hospital patients in the United States receive a vascular access device and many of those patients encounter a vascular access-related complication caused by the use of a polyurethane catheter that can delay their treatment and sometimes lead to infections or even death. PICC and midline complications cost more than $4.5 billion dollars annually and can cost a single, large hospital more than $3 million dollars per year.
“We frequently encounter patients with vascular access complications or polyurethane catheters that need to be replaced and are pleased to have a biomaterial alternative,” said Dr. Roth. “We want our patients to focus on getting healthier, and by reducing complications associated with their vascular access device, we can accelerate their treatment and eventual recovery.”
The unique, patented biomaterial used by Access Vascular in its suite of vascular access devices is designed to avoid these complications and has demonstrated a significant reduction in complications such as occlusions, deep vein thrombosis and phlebitis in recent studies.
“It is a tremendous validation to see our dual-lumen device helping patients,” said James Biggins, CEO of Access Vascular. “Putting this device in the hands of clinicians will help speed treatment and healing while also reducing the overall cost of care for health systems and insurers.”
The HydroPICC Dual-Lumen is a 5 French catheter available in multiple kit configurations. It will be made available over the coming weeks as the newest addition to the expanding family of AVI vascular access devices. AVI plans to continue expansion of its portfolio by adding more peripheral intravenous and central line options.